Case Report

Successful Treatment of Multiple Alopecia Areata With Contact Immunotherapy: Supportive Usage of Oral Antihistamine and Topical Corticosteroid

Maya Kaga-Kamijo, MD, PhD; Shigaku Ikeda, MD, PhD

Department of Dermatology and Allergology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan

ABSTRACT

Contact immunotherapy using diphenylcyclopropenone (DPCP) is a commonly used first-line therapeutic technique for patients with alopecia areata (AA). We present here a successful immunotherapy for AA female case with atopic diathesis, using oral antihistamine and topical corticosteroid supportively on DPCP. Courses of clinical and laboratory findings suggested that indirect effect to allergic inflammation by antihistamine drugs contributed to AA regression in our case.

KEY WORDS: Alopecia areata; Atopic dermatitis; Contact immunotherapy.

ABBREVIATIONS: DPCP: Diphenylcyclopropenone; AA: Alopecia Areata; AD: Atopic Dermatitis; UV: Ultraviolet; PUVA: Phototherapy ultraviolet radiation; UVB: Ultraviolet B.

INTRODUCTION

Alopecia areata (AA) is a most common cause of hair loss, characterized by patchy, confluent, or diffuse hair loss in normal-appearing skin. Area of hair loss usually involve in the scalp and region of the beard, or even on the whole body. Together with clinical presentation of hair-loss, exclamation-mark hairs, cadaver hairs and nail pitting often render the diagnosis of AA. About 16% of AA patients are reported to associate with other allergic or autoimmune diseases including atopic dermatitis (AD), vitiligo, autoimmune thyroid disease. Helpful therapeutic options with immunosuppressive or immune-deviation strategy are suggested to clinician on these days. Among them, only 2 treatments are considered to reach the level of evidence-based medicine; intralesional injection of corticosteroid and contact immunotherapy. Still, there is no curative therapy for AA. On the other hand, ‘modified’ immunotherapy for AA such as combination therapy with contact immunotherapy and steroid pulse and contact immunotherapy without sensitization at a starting point are also reported, currently.

We experienced promoted hair regrowth in refractory multiple AA after the combination therapy of contact immunotherapy using diphenylcyclopropenone (DPCP) with oral bepotastine besilate, oral hydroxyzine hydrochloride and intermitted application of topical corticosteroid.

CASE REPORT

A female case, with a history of polycystic kidney and AD from 27-years-old, experienced onset of AA when she was 40 years old. She has not responded to steroid pulse therapy for one year of intermittent (weekend) oral corticosteroid with targeted ultraviolet (UV) B phototherapy for her scalp. She visited our hospital in 2015, when she was 47-years-old. She neither responded
to 6 months of weekend oral corticosteroid with topical phototherapy ultraviolet radiation (PUVA) for her head, nor 6 months of oral antihistamine and intralesional corticosteroids with ultraviolet B (UVB) irradiation for her body in our hospital. After tapering oral corticosteroid, we began biweekly contact immunotherapy using DPCP on 2016. Simple application of $10^4$-$10^5\%$ DPCP for 3 months aggravated her skin especially in her hairy scalp, ears, face and neck. Hairs of pariental region remained to be completely lost after 3 months of biweekly contact immunotherapy (Figure 1). However, it showed remarkable recovery not only of eczema of her body but also of hair growth after double dose of oral bepotastine besilate (40 mg/day), hydroxyzine hydrochloride (20 mg/day) and topical corticosteroid lotion were added (Figure 2). Application of topical corticosteroid was only permitted in last three days before the day of DPCP application. Changes in laboratory data were shown in Table 1.

**DISCUSSION**

Inducing allergic reaction by applying contact allergens to the affected skin is a principle of contact immunotherapy. Among several reported prognostic factors of contact immunotherapy until today, AD is not a negative factor for DPCP. We have decided to start the therapy on this case because firstly depend on patient’s strong will, secondly depend on this note described above, in spite of concerned aggravation of AD eczema by excessive allergic reaction. Combinative use of oral antihistamine and topical corticosteroid, aimed to cure worsen AD skin symp-

---

**Table 1:** Laboratory Data of the Year 2015-2016. Thymus and Activation-Regulated Chemokine (TARC) was Decreased whereas Serum Immunoglobulin (Ig) E and Eosinophil Level Showed no Remarkable Changes.

<table>
<thead>
<tr>
<th>Date</th>
<th>Therapy</th>
<th>TARC (-450 pg/mL)</th>
<th>IgE (-500 IU/mL)</th>
<th>Eosinophil (70-440 /µL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jan. 2015</td>
<td>Weekend oral corticosteroid</td>
<td>-</td>
<td>517</td>
<td>461</td>
</tr>
<tr>
<td>Aug. 2015</td>
<td>UVB Antihistamine Intrallesional corticosteroid Weekend oral corticosteroid</td>
<td>2416</td>
<td>651</td>
<td>600</td>
</tr>
<tr>
<td>Dec. 2016</td>
<td>DPCP Antihistamine (4 months after changing to bepotastine besilate and hydroxyzine hydrochloride) Topical corticosteroid</td>
<td>985</td>
<td>588</td>
<td>575</td>
</tr>
</tbody>
</table>

**Figure 1:** After 3 Months of DPCP Therapy. Pariental Area of Hair Loss of the Scalp Reached About 70% of the Scalp.

**Figure 2:** After 10 Months of DPCP with Oral Antihistamine and Topical Corticosteroid. AA Patch Nearly Recovered. The Combination Therapy is Being Continued Until Now.
tient whose photographs are involved in the manuscript.

CONSENT

The authors have received oral informed consent from the patient whose photographs are involved in the manuscript.

REFERENCES


CONCLUSIONS

As far as we are aware, this is a first report that ebastine and hydroxyzine hydrochloride showed beneficial effect in an AA patient with AD undergoing contact immunotherapy. Effective and capable combinative options with contact immunotherapy such as anti-allergic inflammation drugs are required for AA patient with AD.

CONFLICTS OF INTEREST

The authors have no conflict of interest to declare.